Exagen, Inc. (XGN)

8.56 +0.14 (+1.66%) USD  |  NASDAQ  |  Oct 15, 16:00
8.54 -0.02 (-0.23%) After-Hours: 20:00
More

Exagen Research and Development Expense (Quarterly) : 1.426M for June 30, 2026

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 1.426M
March 31, 2026 1.553M
December 31, 2025 1.757M
September 30, 2025 1.73M
June 30, 2025 1.483M
March 31, 2025 1.284M
December 31, 2024 1.656M
September 30, 2024 1.481M
June 30, 2024 1.179M
March 31, 2024 1.059M
December 31, 2023 1.076M
September 30, 2023 1.40M
June 30, 2023 1.263M
March 31, 2023 1.126M
December 31, 2022 2.701M
September 30, 2022 2.382M
June 30, 2022 2.689M
March 31, 2022 2.104M
December 31, 2021 2.202M
September 30, 2021 1.74M
June 30, 2021 1.892M
March 31, 2021 1.403M
December 31, 2020 1.165M
Date Value
September 30, 2020 1.018M
June 30, 2020 0.751M
March 31, 2020 0.634M
December 31, 2019 0.566M
September 30, 2019 0.507M
June 30, 2019 0.59M
March 31, 2019 0.513M
December 31, 2018 0.533M
September 30, 2018 0.525M
June 30, 2018 0.545M
March 31, 2018 0.522M
December 31, 2015 0.417M
September 30, 2015 0.311M
June 30, 2015 0.346M
March 31, 2015 0.293M
December 31, 2014 0.347M
September 30, 2014 0.33M
June 30, 2014 0.37M
March 31, 2014 0.24M
December 31, 2013 0.23M
September 30, 2013 0.21M
June 30, 2013 0.226M
March 31, 2013 0.231M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Myriad Genetics, Inc. 25.00M
BioRestorative Therapies, Inc. 1.926M
CareDx, Inc. 22.38M
Natera, Inc. 228.07M
Sera Prognostics, Inc. 3.331M